Latest XEOMIN Stories
On January 9, 2013 the 10-month court injunction on Botox competitor Xeomin expired. Simon Ourian, M.D.
MDLSV now offering Xeomin for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines), months before the full national release, due to the elite status
GREENSBORO, N.C., April 14, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC, maker of XEOMINÂ® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, today announced the launch of the "Make Your Mark" campaign.
GREENSBORO, N.C., March 30, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC announced today that the Centers for Medicare and Medicaid Services (CMS) has granted a unique Healthcare Common Procedure Coding System (HCPCS) billing code, Q2040, for XeominÂ® (incobotulinumtoxinA).
GREENSBORO, N.C., April 13 /PRNewswire/ -- Merz Pharmaceuticals announces that results from several new studies examining XeominÂ® (incobotulinumtoxinA), a botulinum neurotoxin type A (free from complexing proteins), also referred to as NT 201, will be presented today at the 62nd American Academy of Neurology (AAN) annual meeting in Toronto, Canada.